It's Official: IABP Does Not Improve Mortality in Acute MI Patients with Shock

One-year findings from the IABP-SHOCK II trial confirm that use of the device should not be routine in patients who undergo early revascularization.

Short-term data from the IABP-SHOCK II trial (NEJM JW Cardiol Aug 27 2012) showed no survival benefit with intra-aortic balloon counterpulsation (IABP) in patients with acute myocardial infarction (MI) complicated by shock, leading to an adjustment of American and European guideline recommendations from Class I to Class IIa and IIb, respectively. However, in a previous trial, early revascularization in cardiogenic shock, a significant mortality benefit emerged only at extended follow-up (NEJM JW Cardiol Mar 16 2001). Therefore, the, the IABP-SHOCK II researchers now present 12-month follow-up data.

More than 99% of the cohort completed 12-month follow-up. Death rates were similar in the IABP and control groups (52% and 51%, respectively). Ra…

Reviewing Author

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

It's Official: IABP Does Not Improve Mortality in Acute MI Patients with Shock

Topics

Reviewing Author